All
FDA Accepts Application for Zolbetuximab in Gastric, GEJ Cancers
July 10th 2023If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Venclexta Plus Gazyva Induces Minimal Residual Disease, Improves Survival in CLL
July 9th 2023Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.
Frailty Linked With Worse Outcomes, Functional Declines in Older Patients With NSCLC
July 5th 2023Patients 65 years and older with NSCLC and undergoing treatment with immunotherapy, chemotherapy and/or targeted therapy were more likely to have worse survival outcomes and declines in activity of daily living.
Alzheimer’s Disease Medication May Not Improve Cognitive Impairment in Breast Cancer Survivors
July 5th 2023Findings from a study conducted in women with a history of breast cancer demonstrated that treatment with donepezil, which is typically used to treat symptoms of Alzheimer’s disease and dementia, did not improve cognitive impairment, or “chemo brain.”
Immigrant Cancer Survivors Face Higher Rates of Uninsurance, Financial Hardship, Food Insecurity
July 2nd 2023Immigrant and foreign-born cancer survivors experience several disparities that suggest barriers to care and “may portent worse health outcomes in cancer survivorship,” according to researchers.